Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Supportive Care in Cancer
Erschienen in: Supportive Care in Cancer 1/2021

30.07.2020 | Review Article

Taste and smell disturbances in cancer patients: a scoping review of available treatments

verfasst von: Olga Sevryugin, Popi Kasvis, MariaLuisa Vigano, Antonio Vigano

Erschienen in: Supportive Care in Cancer | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Taste and smell disturbances in patients affected by cancer are very common, but often under-recognized symptoms. If not addressed properly, they may impact nutritional status, food enjoyment, and quality of life. Treatment tools available for clinicians to manage chemosensory alterations are limited and are often based on personal clinical experiences. The aim of this study was to assess current oncological and palliative care literature through a scoping review, in order to identify available treatments for taste and smell alterations in cancer patients.

Methods

Medline, Embase, CINAHL, ProQuest Dissertations and Theses, and Google Scholar were searched from inception until January 2020, with subject headings relevant to the domains of chemosensory alterations, palliative, and cancer care. A total of 10,718 English and French language publications were reviewed, yielding 43 articles on the researched topic.

Results

The heterogeneity of selected articles led to difficulties in interpretation and analysis of the available evidence. Included publications differed in study design, population sample, anticancer treatments, and measures of assessment for taste and smell disturbances. A broad variety of treatment options were described including zinc and polaprezinc, radio-protectors, vitamins and supplements, anti-xerostomia agents, active swallowing exercises, nutritional interventions, delta-9-tetrahydrocannabinol, and photobiomodulation.

Conclusion

This scoping review identifies the current state of knowledge regarding chemosensory alterations within supportive cancer care. Despite not reaching firm conclusions, this article offers therapeutic venues to further explore in larger and more methodologically sound studies.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Spotten LE, Corish CA, Lorton CM, Ui Dhuibhir PM, O’Donoghue NC, O’Connor B, Walsh TD (2017) Subjective and objective taste and smell changes in cancer. Ann Onc 28(5):969–984CrossRef
2.
Gamper EM, Zabernigg A, Wintner LM, Giesinger JM, Oberguggenberger A, Kemmler G, Sperner-Unterweger B, Holzner B (2012) Coming to your senses: detecting taste and smell alterations in chemotherapy patients. A systematic review. J. Pain Symptom Manag 44(6):880–895CrossRef
3.
Gill SS, Frew J, Fry A, Adam J, Paleri V, Dobrowsky W, Chatterjee S, Kelly CG (2011) Priorities for the head and neck cancer patient, their companion and members of the multidisciplinary team and decision regret. Clinical Oncology 23(8):518–524PubMedCrossRef
4.
Hutton JL, Baracos VE, Wismer VW (2007) Chemosensory dysfunction is a primary factor in the evolution of declining nutritional status and quality of life in patients with advanced cancer. J Pain Symptom Manag 33(2):156–165CrossRef
5.
Boltong A, Keast R, Aranda S (2012) Experiences and consequences of altered taste, flavour and food hedonics during chemotherapy treatment. Support Care Cancer 20(11):2765–2774PubMedCrossRef
6.
Wrobel BB, Leopold DA (2004) Clinical assessment of patients with smell and taste disorders. Otolaryngol Clin N Am 37(6):1127–1142CrossRef
7.
Epstein JB, Smutzer G, Doty RL (2016) Understanding the impact of taste changes in oncology care. Support Care Cancer 24(4):1917–1931
8.
Amézaga J, Alfaro B, Rios Y, Larraiox A, Ugartemendia G, Urruticoechea A, Tueros I (2018) Assessing taste and smell alterations in cancer patients undergoing chemotherapy according to treatment. Support Care Cancer 26(12):4077–4086PubMedCrossRef
9.
van der Werf A, Rovithi M, Langius JA, de van der Schueren MA, Verheul HM (2017) Insight in taste alterations during treatment with protein kinase inhibitors. Eur J Cancer 86:125–134PubMedCrossRef
10.
Murtaza B, Hichami A, Khan AS, Ghiringhelli F, Khan NA (2017) Alteration in taste perception in cancer: causes and strategies of treatment. Front Physiol 8:134PubMedPubMedCentralCrossRef
11.
Spotten L, Corish C, Lorton C, Dhuibhir PU, O’Donoghue N, O’Connor B, Cunningham M, El Beltagi N, Gillham C, Walsh D (2016) Subjective taste and smell changes in treatment-naive people with solid tumours. Support Care Cancer 24(7):3201–3208PubMed
12.
13.
Arksey H, O’Malley L (2005) Scoping studies: towards a methodological framework. Int J Soc 8(1):19–32
14.
Erkurt E, Erkisi M, Tunali C (2000) Supportive treatment in weight-losing cancer patients due to the additive adverse effects of radiation treatment and/or chemotherapy. J Exp Clin Cancer Res 19(4):431–439PubMed
15.
Thorne T, Olson K, Wismer W (2015) A state-of-the-art review of the management and treatment of taste and smell alterations in adult oncology patients. Support Care Cancer 23(9):2843–2851PubMedCrossRef
16.
Ripamonti C, Zecca E, Brunelli C, Fulfaro F, Villa S, Balzarini A, Bombardieri E, Conno FD (1998) A randomized, controlled clinical trial to evaluate the effects of zinc sulfate on cancer patients with taste alterations caused by head and neck irradiation. Cancer 82(10):1938–1945PubMedCrossRef
17.
Najafizade N, Hemati S, Gookizade A, Berjis N, Hashemi M, Vejdani S, Ghannadi A, Shahsanaee A, Arbab N (2013) Preventive effects of zinc sulfate on taste alterations in patients under irradiation for head and neck cancers: a randomized placebo-controlled trial. J Res Med Sci 18(2):123–126PubMedPubMedCentral
18.
Yamagata T, Nakamura Y, Yamagata Y, Nakanishi M, Matsunaga K, Nakanishi H, Nishimoto T, Minakata Y, Mune M, Yukawa S (2003) The pilot trial of the prevention of the increase in electrical taste thresholds by zinc containing fluid infusion during chemotherapy to treat primary lung cancer. J Exp Clin Cancer Res 22(4):557–563PubMed
19.
Silverman JE (1983) Zinc supplementation and taste in head and neck cancer patients undergoing radiation therapy. J Oral Med 38:14–16PubMed
20.
Silverman S Jr, Thompson JS (1984) Serum zinc and copper in oral/oropharyngeal carcinoma. A study of seventy-five patients. Oral Surg Oral Med Oral Pathol 57(1):34–36PubMedCrossRef
21.
Khan AH, Safdar J, Siddiqui SU (2019) Efficacy of zinc sulfate on concurrent chemoradiotherapy induced taste alterations in oral cancer patients: a double blind randomized controlled trial. Pak J Med Sci 35(3):624–629PubMedPubMedCentral
22.
Halyard MY, Jatoi A, Sloan JA, Bearden JD III, Vora SA, Atherton PJ, Perez EA, Soori G, Zalduendo AC, Zhu A, Stella PJ (2007) Does zinc sulfate prevent therapy-induced taste alterations in head and neck cancer patients? Results of phase III double-blind, placebo-controlled trial from the North Central Cancer Treatment Group (N01C4). Int J Radiat Oncol Biol Phys 67(5):1318–1322PubMedCrossRef
23.
Lyckholm L, Heddinger SP, Parker G, Coyne PJ, Ramakrishnan V, Smith TJ, Henkin RI (2012) A randomized, placebo-controlled trial of oral zinc for chemotherapy-related taste and smell disorders. J Pain Palliat Care Pharmacother 26(2):111–114PubMedPubMedCentralCrossRef
24.
Fujii H, Hirose C, Ishihara M, Iihara H, Imai H, Tanaka Y, Matsuhashi N, Takahashi T, Yamaguchi K, Yoshida K, Suzuki A (2018) Improvement of dysgeusia by polaprezinc, a zinc-L-carnosine, in outpatients receiving cancer chemotherapy. Anticancer Res 38(11):6367–6373PubMedCrossRef
25.
Watanabe T, Ishihara M, Matsuura K, Mizuta K, Itoh Y (2010) Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer. Int J Cancer 127(8):1984–1990PubMedCrossRef
26.
Hayashi H, Kobayashi R, Suzuki A, Ishihara M, Nakamura N, Kitagawa J, Kanemura N, Kasahara S, Kitaichi K, Hara T, Tsurumi H (2014) Polaprezinc prevents oral mucositis in patients treated with high-dose chemotherapy followed by hematopoietic stem cell transplantation. Anticancer Res 34(12):7271–7277PubMed
27.
Büntzel J, Riesenbeck D, Glatzel M, Berndt-Skorka R, Riedel T, Mücke R, Kisters K, Schönekaes KG, Schäfer U, Bruns F, Micke O (2010) Limited effects of selenium substitution in the prevention of radiation-associated toxicities. Results of a randomized study in head and neck cancer patients. Anticancer Res 30(5):1829–1832PubMed
28.
Büntzel J, Schuth J, Küttner K, Glatzel (1998) Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Support Care Cancer 6(2):155–160PubMedCrossRef
29.
Büntzel J, Glatzel M, Muecke R, Micke O, Bruns F (2007) Influence of amifostine on late radiation-toxicity in head and neck cancer-a follow-up study. Anticancer Res 27(4A):1953–1956PubMed
30.
Brisbois TD, De Kock IH, Watanabe SM, Mirhosseini M, Lamoureux DC, Chasen M, MacDonald N, Baracos VE, Wismer WV (2011) Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Ann Oncol 22(9):2086–2093PubMedCrossRef
31.
Strasser F, Demmer R, Böhme C, Schmitz SFH, Thuerlimann B, Cerny T, Gillessen S (2008) Prevention of docetaxel- or paclitaxel-associated taste alterations in cancer patients with oral glutamine: a randomized, placebo-controlled, double-blind study. Oncologist 13(3):337–346PubMedCrossRef
32.
Wang A, Duncan SE, Lesser GJ, Ray WK, Dietrich AM (2018) Effect of lactoferrin on taste and smell abnormalities induced by chemotherapy: a proteome analysis. Food Funct 9(9):4948–4958PubMedCrossRef
33.
Pattison R (1999) Alteration in taste perception and its relationship with nutritional status and quality of life in patients with advanced cancer. Dissertation, The Open University
34.
Andersson G, Johansson G, Attström R, Edwardsson S, Glantz PO, Larsson K (1995) Comparison of the effect of the linseed extract Salinum® and a methyl cellulose preparation on the symptoms of dry mouth. Gerodontology 12(1):12–17PubMedCrossRef
35.
Jordan WO, Duckert A, Borberg SK, Trog D, Wildfang I (2012) Management of xerostomia with artificial saliva (Xerotin). Eur Arch Oto-Rhino-L 269(4):1384
36.
Nakada K, Ishibashi T, Takei T, Hirata K, Shinohara K, Katoh S, Zhao S, Tamaki N, Noguchi Y, Noguchi S (2005) Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? J. Nucl. Med 46(2):261–266PubMed
37.
Banava S, Houshyari M, Safaie T (2015) The effect of casein phosphopeptide amorphous calcium phosphate fluoride paste (CPP-ACPF) on oral and salivary conditions of patients undergoing chemotherapy: a randomized controlled clinical trial. Electron Physician 7(7):1535–1541PubMedPubMedCentralCrossRef
38.
Epstein JB, Emerton S, Le ND, Stevenson-Moore P (1999) A double-blind crossover trial of Oral Balance gel and Biotene toothpaste versus placebo in patients with xerostomia following radiation therapy. Oral Oncol 35(2):132–137PubMedCrossRef
39.
Momm F, Volegova-Neher NJ, Schulte-Möntig J, Guttenberger R (2005) Different saliva substitutes for treatment of xerostomia following radiotherapy. A prospective crossover study. Strahlenther Onkol 181(4):231–236PubMedCrossRef
40.
Schuller DE, Stevens P, Clausen KP, Olsen J, Gahbauer R, Martin M (1989) Treatment of radiation side effects with oral pilocarpine. J Surg Oncol 42(4):272–276PubMedCrossRef
41.
Fisher J, Scott C, Scarantino CW, Leveque FG, White RL, Rotman M, Hodson DI, Meredith RF, Foote R, Bachman DG, Lee N (2003) Phase III quality-of-life study results: impact on patients’ quality of life to reducing xerostomia after radiotherapy for head-and-neck cancer-RTOG 97-09. Int J Radiat Oncol Biol Phys 56(3):832–836PubMedCrossRef
42.
Jham BC, Chen H, Carvalho AL, Freire AR (2009) A randomized phase III prospective trial of bethanechol to prevent mucositis, candidiasis, and taste loss in patients with head and neck cancer undergoing radiotherapy: a secondary analysis. J Oral Sci 51(4):565–572PubMedCrossRef
43.
Wilhelm-Buchstab T, Thelen C, Amecke-Mönnighoff F, Schmeel LC, Simon B, Müdder T, Schoroth F, Garbe S, Röhner F, Vornholt S, Schröck A (2019) Pilot study: protective effect on mucosal tissue using dental waterjet and dexpanthenol rinsing solution during radiotherapy in head and neck tumor patients. Oral Cancer 3(3–4):59–67CrossRef
44.
Mastroianni C, Magnani C, Giannarelli D, Stefanelli MC, Di Cienzo V, Valerioti T, Casale G, Levano M, Castelli M, Altariva R, Palumbo S, De Leo E, Bosso F, Santilli S, Failla A, Fiumara S, Graziani M (2018) Oral care in a sample of patients undergoing palliative care: a prospective single-centre observational study: Igor study. Palliat Med 32(1):45–46
45.
El Mobadder M, Farhat F, El Mobadder W, Nammour S (2019) Photobiomodulation therapy in the treatment of oral mucositis, dysgeusia and oral dryness as side-effects of head and neck radiotherapy in a cancer patient: a case series. Int J Environ Res Public Health 16(22):4505PubMedCentralCrossRef
46.
Morais MO, Martins AF, de Jesus AP, de Sousa Neto SS, da Costa AW, Pereira CH, Oton-Leite AF, de Freitas NM, Leles CR, Mendonça EF (2020) A prospective study on oral adverse effects in head and neck cancer patients submitted to a preventive oral care protocol. Support Care Cancer 3(1):1–11
47.
Carnaby-Mann G, Crary MA, Schmalfuss I, Amdur R (2012) “Pharyngocise”: randomized controlled trial of preventative exercises to maintain muscle structure and swallowing function during head-and-neck chemoradiotherapy. Int J Radiat Oncol Biol Phys 83(1):210–219PubMedCrossRef
48.
Risberg-Berlin B, Karlsson TR, Tuomi L, Finizia C (2014) Effectiveness of olfactory rehabilitation according to a structured protocol with potential of regaining pre-operative levels in laryngectomy patients using nasal airflow-inducing manoeuvre. Eur Arch Oto-Rhino-L 271(5):1113–1119CrossRef
49.
Von Grundherr J, Koch B, Grimm D, Salchow J, Valentini L, Hummel T, Bokemeyer C, Stein A, Mann J (2019) Impact of taste and smell training on taste disorders during chemotherapy–TasTe trial. Cancer Manag Res 11:4493–4504CrossRef
50.
Ravasco P, Monteiro-Grillo I, Marques Vidal P, Camilo ME (2005) Impact of nutrition on outcome: a prospective randomized controlled trial in patients with head and neck cancer undergoing radiotherapy. Head Neck 27(8):659–668PubMedCrossRef
51.
Rehwaldt M, Wickham R, Purl S, Tariman J, Blendowski C, Shott S, Lappe M (2009) Self-care strategies to cope with taste changes after chemotherapy. Oncol Nurs Forum 36(2):E47–E56PubMedPubMedCentralCrossRef
52.
Williams SA, Schreier AM (2004) The effect of education in managing side effects in women receiving chemotherapy for treatment of breast cancer. Oncol Nurs Forum 31(1):E16–E23PubMedCrossRef
53.
Schiffman SS, Sattely-Miller EA, Taylor EL, Graham BG, Landerman LR, Zervakis J, Campagna LK, Cohen HJ, Blackwell S, Garst JL (2007) Combination of flavor enhancement and chemosensory education improves nutritional status in older cancer patients. J Nutr Health Aging 11(5):439–454PubMed
54.
Russ JE, DeWys WD (1978) Correction of taste abnormality of malignancy with intravenous hyperalimentation. Arch of Intern Med 138(5):799–800CrossRef
55.
Wilken MK, Satiroff BA (2012) Pilot study of “miracle fruit” to improve food palatability for patients receiving chemotherapy. Clin J Oncol Nurs 16(5):E173–E177PubMedCrossRef
56.
Cusnir M, Soares H, Schwartz M, Pizzolato J, Ludsky J, Campbell R, Lilenbaum R (2012) Treatment of taste alterations in chemotherapy patients using “miracle fruit”: P1-31. Psycho-Oncology 21:58
57.
Velargo PA, Samant S (2012) Synsepalum dulcificum and varied taste occurring postradiation trial. Otolaryngol Head Neck Surg 147(2_suppl):178CrossRef
58.
Yanagimoto H, Satoi S, Toyokawa H, Yamamoto T, Hirooka S, Yamao J, Araki H, Matsui Y, Kwon AH (2009) The beneficial effect of active hexose correlated compound (AHCC), a health food component, in patients with pancreatic or biliary tract cancer who underwent chemotherapy. Pancreas. Conference: Joint 40th Anniversary Meeting of American Pancreatic Association and Japan Pancreas Society. 38(8):1063
59.
Ikeda M, Hirai R, Shigihara S, Ikui A (2008) Taste disorders and zinc deficiency. Int J Med Sci 6(3):105–111
60.
Dajani EZ, Klamut MJ (2000) Novel therapeutic approaches to gastric and duodenal ulcers: an update. Expert Opin Investig Drugs 9(7):1537–1544PubMedCrossRef
61.
Arthur JR (2000) The glutathione peroxidases. Cell Mol Life Sci 57(13–14):1825–1835PubMed
62.
Savarese DM, Savy G, Vahdat L, Wischmeyer PE, Corey B (2003) Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treat Rev 29(6):501–513PubMedCrossRef
63.
Heckmann JG, Heckmann SM, Lang CJ, Hummel T (2003) Neurological aspects of taste disorders. Arch Neurol 60(5):667–671PubMedCrossRef
64.
Siqueiros-Cendón T, Arévalo-Gallegos S, Iglesias-Figueroa BF, García-Montoya IA, Salazar-Martínez J, Rascón-Cruz Q (2014) Immunomodulatory effects of lactoferrin. Acta Pharmacol Sin 35(5):557–566PubMedPubMedCentralCrossRef
65.
Ömür-Özbek P, Dietrich AM, Duncan SE, Lee Y (2012) Role of lipid oxidation, chelating agents, and antioxidants in metallic flavor development in the oral cavity. J Agric Food Chem 60(9):2274–2280PubMedCrossRef
66.
Wong JM, Kern M (2011) Miracle fruit improves sweetness of a low-calorie dessert without promoting subsequent energy compensation. Appetite 56(1):163–166PubMedCrossRef
67.
Schiffman SS, Graham BG, Sattely-Miller EA, Zervakis J, Welsh-Bohmer K (2002) Taste, smell and neuropsychological performance of individuals at familial risk for Alzheimer’s disease. Neurobiol Aging 23(3):397–404PubMedCrossRef
Metadaten
Titel
Taste and smell disturbances in cancer patients: a scoping review of available treatments
verfasst von
Olga Sevryugin
Popi Kasvis
MariaLuisa Vigano
Antonio Vigano
Publikationsdatum
30.07.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 1/2021
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-020-05609-4

Weitere Artikel der Ausgabe 1/2021

Supportive Care in Cancer 1/2021 Zur Ausgabe

Original Article

Obstructive sleep apnea in head and neck cancer survivors

Original Article

Healthcare resource utilization in advanced non-small-cell lung cancer: post hoc analysis of the randomized phase 3 REVEL study

Original Article

Being beneficial to self and caregiver: the role of dispositional mindfulness among breast cancer patients

Original Article

A retrospective cohort study to investigate the incidence of cancer-related weight loss during chemotherapy in gastric cancer patients

Original Article

When they stop drinking—examining end-of-life hydration practices and death rattle occurrence

Original Article

Strategies to identify hepatitis C virus infection in patients receiving anticancer therapy: a cross-sectional study

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise